Kane Biotech Inc (KNE) Fair Value & Analysis
Healthcare · CA · Market cap C$6.2M
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 7 days ago
Share price −25.0% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.0300 – C$0.0600 · the C$0.0300 price screens above the C$0.0100 fair value. As of Jun 23, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Kane Biotech Inc (KNE) currently trades at C$0.0300, while our model-based Fair Value estimate is C$0.0100 — implying the stock looks roughly 66.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at C$58.6K. Revenue declined 89.5% year over year. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kane Biotech Inc reported revenue of C$428K in FY2025 versus C$1.6M in FY2021, a compound −28.2%/yr. Reported net income was −C$2.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kane Biotech Inc (KNE) undervalued?
What is the fair value of KNE?
What is the quality score of KNE?
What is the revenue of Kane Biotech Inc (KNE)?
What is the net profit margin of KNE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.